Pablo E. Vivas‐Mejía

Author

The University of Texas MD Anderson Cancer Center ORCID

Also Known As

Jaladurgam, Padmavathi, P E Vivas-Mejia, P E. Vivas-Mejia, P Vivas-Mejia, P Vivas-Mejía, P Vivas‐Mejia, P. E. Vivas-Mejia, P.E. Vivas-Mejia, P.E. Vivas‐Mejía, Pablo E Vivas-Mejía

192

Publications

Citations

H-Index

Concepts

All Affiliations

The University of Texas MD Anderson Cancer Center University of Puerto Rico System University of Puerto Rico at Río Piedras University of Puerto Rico, Medical Sciences Campus The University of Texas Health Science Center at Houston

About

Pablo E. Vivas‐Mejía is an author at The University of Texas MD Anderson Cancer Center specializing in medicine, cell biology, and tumor biology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	18	21	1.5K
2	Health Sciences	3	3	185
3	Engineering	2	2	171
4	Natural Sciences	2	2	89
5	Social Sciences	1	1	60

Pablo E. Vivas‐Mejía

Publications

3.7K

Citations

H-Index

Page 1

	Year	Citations
Sustained Small Interfering RNA Delivery by Mesoporous Silicon Particles Takemi Tanaka, Lingegowda S. Mangala, Pablo E. Vivas‐Mejía, Cancer Research	2010	316
Adrenergic modulation of focal adhesion kinase protects human ovarian cancer cells from anoikis Anil K. Sood, Guillermo N. Armaiz-Peña, Jyotsnabaran Halder, Journal of Clinical Investigation Chronic StressAdrenergic ModulationFocal Adhesion KinaseSignaling PathwayReceptor Tyrosine Kinase	2010	271
Src activation by β-adrenoreceptors is a key switch for tumour metastasis Guillermo N. Armaiz-Peña, Julie K. Allen, Anthony Cruz, Nature Communications Tumor BiologyMolecular PhysiologyTumour MetastasisMedicinePharmacology	2013	199
Stress Effects on FosB- and Interleukin-8 (IL8)-driven Ovarian Cancer Growth and Metastasis Mian M.K. Shahzad, Jesusa M.G. Arevalo, Guillermo N. Armaiz-Peña, Journal of Biological Chemistry	2010	185
Targeting Melanoma Growth and Metastasis with Systemic Delivery of Liposome-Incorporated Protease-Activated Receptor-1 Small Interfering RNA Gabriel J. Villares, Maya Zigler, Hua Wang, Cancer Research	2008	165
Therapeutic Targeting of ATP7B in Ovarian Carcinoma Lingegowda S. Mangala, Vesna Zuzel, Rosemarie Schmandt, Clinical Cancer Research	2009	151
Nanoparticles as Drug Delivery Systems in Cancer Medicine: Emphasis on RNAi-Containing Nanoliposomes Mónica F. Díaz, Pablo E. Vivas‐Mejía Pharmaceuticals NanoparticlesNanomedicineNovel NanoparticlesEngineeringTherapeutic Nanomaterials	2013	146
SIK2 Is a Centrosome Kinase Required for Bipolar Mitotic Spindle Formation that Provides a Potential Target for Therapy in Ovarian Cancer Ahmed A. Ahmed, Zhen Lü, Nicholas B. Jennings, Cancer Cell Signaling PathwayCell DivisionMedicineCentrosome Kinase RequiredProtein Kinase	2010	142
Nuclear Factor-κB p65/relA Silencing Induces Apoptosis and Increases Gemcitabine Effectiveness in a Subset of Pancreatic Cancer Cells Xue Pan, Thiruvengadam Arumugam, Tameyoshi Yamamoto, Clinical Cancer Research	2008	127
Targeting c-MYC in Platinum-Resistant Ovarian Cancer Jeyshka M. Reyes‐González, Guillermo N. Armaiz-Peña, Lingegowda S. Mangala, Molecular Cancer Therapeutics	2015	122

Page 1